Teknova Q1 revenue $11.1M (+23% YoY); guides FY2022 revenue $45-48M

Alpha Teknova, Inc.

2023-Q1 EPS reported -$0.20 revenue$11,147,000

Q1 2022 revenue $11.1M up 23% YoY; Lab Essentials $6.98M, Clinical Solutions $3.81M, Sample Transport $6K.
Net loss -$5.5M (-$0.20 diluted EPS) vs -$0.7M loss in Q1 2021; Adjusted EBITDA -$4.3M vs break-even.
Cash position $76.5M; amended credit facility increased from $27M to $57M to fund growth.
FY2022 revenue guidance of $45-48M (over 30% growth at midpoint); Lab Essentials ~25% growth, Clinical Solutions at least 60%.
No material Sample Transport revenue expected in 2022; new manufacturing facility expected online by year end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.